查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1435104

Alpha1 抗胰蛋白酶缺乏症治療藥物市場：治療方法、給藥途徑、通路 - 全球預測 2024-2030

Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment (Augmentation Therapy, Bronchodilators, Corticosteroids), Route of Administration (Inhalation, Injection, Oral), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

α1-抗胰蛋白酶缺乏症治療市場規模預計到2023年為30.2億美元，2024年達到32.6億美元，預計到2030年將達到55.7億美元，複合年成長率為9.15%。

α-1抗胰蛋白酶缺乏症藥物的全球市場

主要市場統計
基準年[2023] 30.2億美元
預測年份 [2024] 32.6億美元
預測年份 [2030] 55.7億美元
複合年成長率（%） 9.15%
α1抗胰蛋白酶缺乏症治療藥物市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估α1-抗胰蛋白酶缺乏藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對 Alpha-1 抗胰蛋白酶缺乏症治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-α1抗胰蛋白酶缺乏症治療藥物市場的市場規模與預測是多少？

在 2-α1 抗胰蛋白酶缺乏治療藥物市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-α1抗胰蛋白酶缺乏症治療藥物市場的技術趨勢和法律規範是什麼？

4-α1抗胰蛋白酶缺乏症治療藥物市場主要供應商的市場佔有率為何？

進入5-α1抗胰蛋白酶缺乏症藥物市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人群中 α1-抗胰蛋白酶缺乏症的發生率不斷增加
      • 提高早期診斷和預防保健的意識
    • 抑制因素
      • 研發成本高且缺乏熟練的專業人員
    • 機會
      • 新型 α-1 抗胰蛋白酶缺乏症治療方法的最新研究
      • 增加投資以實現醫療基礎設施現代化
    • 任務
      • α1-抗胰蛋白酶缺乏症診斷的局限性
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章 Alpha1 抗胰蛋白酶缺乏症治療藥物市場（依治療）

  • 強化治療
  • 支氣管擴張劑
  • 皮質類固醇
  • 氧氣療法

第7章 Alpha1 抗胰蛋白酶缺乏症治療藥物市場：依給藥途徑

  • 吸入
  • 注射
  • 口服

第8章 Alpha1 抗胰蛋白酶缺乏症治療藥物市場：按分銷管道

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上的

第9章北美和南美Alpha1抗胰蛋白酶缺乏症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區Alpha1抗胰蛋白酶缺乏症治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的α1-抗胰蛋白酶缺乏症治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • Abeona Therapeutics Inc
    • Alnylam Pharmaceuticals, Inc.
    • Apic Bio
    • Arrowhead Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Baxter International Inc.
    • Cedars-Sinai Health System
    • Centessa Pharmaceuticals PLC
    • Chiesi Farmaceutici SpA
    • CSL Limited
    • Curaxys SL
    • Dicerna Pharmaceuticals, Inc
    • GlaxoSmithKline PLC
    • Grifols, SA
    • Inhibrx, Inc.
    • Intellia Therapeutics, Inc.
    • Kamada Ltd.
    • Krystal Biotech, Inc.
    • LFB Biomedicaments SA
    • Mereo Biopharma Group PLC
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • PH PHARMA CO. LTD
    • Takeda Pharmaceutical Company Limited
    • Vertex Pharmaceuticals Incorporated
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-C002B1C99874

[198 Pages Report] The Alpha 1 Antitrypsin Deficiency Treatment Market size was estimated at USD 3.02 billion in 2023 and expected to reach USD 3.26 billion in 2024, at a CAGR 9.15% to reach USD 5.57 billion by 2030.

Global Alpha 1 Antitrypsin Deficiency Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 3.02 billion
Estimated Year [2024] USD 3.26 billion
Forecast Year [2030] USD 5.57 billion
CAGR (%) 9.15%
Alpha 1 Antitrypsin Deficiency Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alpha 1 Antitrypsin Deficiency Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alpha 1 Antitrypsin Deficiency Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alpha 1 Antitrypsin Deficiency Treatment Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc, Alnylam Pharmaceuticals, Inc., Apic Bio, Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Cedars-Sinai Health System, Centessa Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., CSL Limited, Curaxys S.L., Dicerna Pharmaceuticals, Inc, GlaxoSmithKline PLC, Grifols, S.A., Inhibrx, Inc., Intellia Therapeutics, Inc., Kamada Ltd., Krystal Biotech, Inc., LFB Biomedicaments S.A., Mereo Biopharma Group PLC, Novo Nordisk A/S, Pfizer, Inc., PH PHARMA CO. LTD, Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Alpha 1 Antitrypsin Deficiency Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Augmentation Therapy
    • Bronchodilators
    • Corticosteroids
    • Oxygen Therapy
  • Route of Administration
    • Inhalation
    • Injection
    • Oral
  • Distribution Channel
    • Offline
      • Hospital Pharmacy
      • Retail Pharmacy
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Alpha 1 Antitrypsin Deficiency Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alpha 1 Antitrypsin Deficiency Treatment Market?

3. What are the technology trends and regulatory frameworks in the Alpha 1 Antitrypsin Deficiency Treatment Market?

4. What is the market share of the leading vendors in the Alpha 1 Antitrypsin Deficiency Treatment Market?

5. Which modes and strategic moves are suitable for entering the Alpha 1 Antitrypsin Deficiency Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Alpha 1 Antitrypsin Deficiency Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of alpha 1 antitrypsin deficiency among population
      • 5.1.1.2. Growing awareness about early diagnosis and preventive care
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with R&D and dearth of skilled professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging research on new alpha 1 antitrypsin deficiency treatments
      • 5.1.3.2. Increasing investments to modernize healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations associated with a diagnosis of alpha 1 antitrypsin deficiency
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Alpha 1 Antitrypsin Deficiency Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Augmentation Therapy
  • 6.3. Bronchodilators
  • 6.4. Corticosteroids
  • 6.5. Oxygen Therapy

7. Alpha 1 Antitrypsin Deficiency Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Injection
  • 7.4. Oral

8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail Pharmacy
  • 8.3. Online

9. Americas Alpha 1 Antitrypsin Deficiency Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abeona Therapeutics Inc
    • 13.1.2. Alnylam Pharmaceuticals, Inc.
    • 13.1.3. Apic Bio
    • 13.1.4. Arrowhead Pharmaceuticals, Inc.
    • 13.1.5. AstraZeneca PLC
    • 13.1.6. Baxter International Inc.
    • 13.1.7. Cedars-Sinai Health System
    • 13.1.8. Centessa Pharmaceuticals PLC
    • 13.1.9. Chiesi Farmaceutici S.p.A.
    • 13.1.10. CSL Limited
    • 13.1.11. Curaxys S.L.
    • 13.1.12. Dicerna Pharmaceuticals, Inc
    • 13.1.13. GlaxoSmithKline PLC
    • 13.1.14. Grifols, S.A.
    • 13.1.15. Inhibrx, Inc.
    • 13.1.16. Intellia Therapeutics, Inc.
    • 13.1.17. Kamada Ltd.
    • 13.1.18. Krystal Biotech, Inc.
    • 13.1.19. LFB Biomedicaments S.A.
    • 13.1.20. Mereo Biopharma Group PLC
    • 13.1.21. Novo Nordisk A/S
    • 13.1.22. Pfizer, Inc.
    • 13.1.23. PH PHARMA CO. LTD
    • 13.1.24. Takeda Pharmaceutical Company Limited
    • 13.1.25. Vertex Pharmaceuticals Incorporated
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET DYNAMICS
  • FIGURE 7. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 6. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 17. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 188. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 189. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET LICENSE & PRICING